Your browser is no longer supported. Please, upgrade your browser.
Settings
NBIX Neurocrine Biosciences, Inc. daily Stock Chart
NBIX [NASD]
Neurocrine Biosciences, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own1.10% Shs Outstand92.55M Perf Week-0.80%
Market Cap10.10B Forward P/E57.61 EPS next Y1.90 Insider Trans-24.50% Shs Float89.18M Perf Month-8.74%
Income-52.00M PEG- EPS next Q0.46 Inst Own- Short Float4.75% Perf Quarter3.24%
Sales323.30M P/S31.25 EPS this Y0.50% Inst Trans0.39% Short Ratio5.47 Perf Half Y39.19%
Book/sh4.19 P/B26.05 EPS next Y935.52% ROA-6.40% Target Price134.46 Perf Year84.94%
Cash/sh5.50 P/C19.86 EPS next 5Y- ROE-14.20% 52W Range57.71 - 126.98 Perf YTD40.70%
Dividend- P/FCF5943.34 EPS past 5Y- ROI-17.70% 52W High-14.03% Beta0.86
Dividend %- Quick Ratio- Sales past 5Y24.90% Gross Margin99.10% 52W Low89.17% ATR4.26
Employees400 Current Ratio9.20 Sales Q/Q1429.70% Oper. Margin-10.30% RSI (14)40.06 Volatility3.54% 3.76%
OptionableYes Debt/Eq1.00 EPS Q/Q90.40% Profit Margin-16.10% Rel Volume0.95 Prev Close112.01
ShortableYes LT Debt/Eq1.00 EarningsNov 05 AMC Payout- Avg Volume775.26K Price109.17
Recom1.60 SMA20-5.65% SMA50-7.13% SMA20012.02% Volume737,220 Change-2.54%
Sep-10-18Initiated Morgan Stanley Overweight $145
Aug-07-18Initiated Stifel Buy $137
Feb-22-18Reiterated Needham Buy $95 → $110
Nov-02-17Reiterated H.C. Wainwright Buy $130 → $139
May-10-17Reiterated H.C. Wainwright Buy $100 → $130
May-05-17Initiated BofA/Merrill Buy $70
Jan-27-17Upgrade Oppenheimer Perform → Outperform
Nov-22-16Initiated Oppenheimer Perform
Nov-03-16Initiated Deutsche Bank Buy $65
Oct-18-16Initiated Needham Buy $62
Oct-04-16Resumed Leerink Partners Outperform $70
Jun-29-16Initiated H.C. Wainwright Buy $80
Oct-12-15Reiterated Leerink Partners Outperform $67 → $71
Oct-08-15Reiterated Piper Jaffray Overweight $86 → $96
Sep-16-15Reiterated Piper Jaffray Overweight $82 → $86
Aug-18-15Resumed Jefferies Buy
May-22-15Reiterated Piper Jaffray Overweight $56 → $64
May-22-15Reiterated Nomura Buy $61 → $69
Mar-04-15Initiated Barclays Overweight $60
Feb-10-15Reiterated Deutsche Bank Buy $35 → $45
Oct-15-18 04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2018 Financial Results PR Newswire
08:35AM  New Research: Key Drivers of Growth for Neurocrine Biosciences, SS&C Technologies, Quaker Chemical, Sealed Air, KLA-Tencor, and Summit Hotel Properties Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Tesaro and Neurocrine Biosciences ACCESSWIRE
Oct-10-18 04:54PM  Neurocrine Inks Deal with Private Biotech to Make CNS Drugs Zacks
Oct-09-18 04:01PM  Neurocrine Biosciences and Jnana Therapeutics Enter Strategic Collaboration to Discover Novel Medicines to Treat Central Nervous System Disorders PR Newswire
Oct-08-18 11:51AM  AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis Zacks
Oct-05-18 05:13PM  AbbVie Receives Health Canada Approval of ORILISSA (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis CNW Group
09:30AM  UTHR vs. NBIX: Which Stock Is the Better Value Option? Zacks
Oct-01-18 04:01PM  Neurocrine Biosciences to Present New Long-Term Data Analyses on INGREZZA® (valbenazine) at the 2018 International Congress of Parkinson's Disease and Movement Disorders PR Newswire
Sep-30-18 03:30PM  Here's What Could Cause Neurocrine Biosciences Shares to Skyrocket Motley Fool
Sep-28-18 11:33AM  Healthcare: 2 Hot Biotech Stocks on Our Radar Motley Fool
Sep-10-18 04:10PM  A Double Pair Trade: Morgan Stanley Buys 2 Biotechs, Sells 2 Others Benzinga
Sep-07-18 03:57PM  Stock Market Forecast: More Gains, More Volatility Investor's Business Daily
Sep-05-18 04:01PM  Neurocrine Biosciences to Present at the Morgan Stanley 16th Annual Global Healthcare Conference PR Newswire
Aug-22-18 08:30AM  AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids PR Newswire
Aug-20-18 06:03PM  Edited Transcript of NBIX earnings conference call or presentation 31-Jul-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-15-18 04:01PM  Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congress on Parkinson's Disease and Related Disorders PR Newswire
Aug-13-18 07:50AM  Report: Developing Opportunities within Energy Recovery, Lamb Weston, Neurocrine Biosciences, Pioneer Natural Resources, Meritor, and Ophthotech Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-07-18 11:07AM  4 Reasons Behind Stifel's Neurocrine Bull Thesis Benzinga
Aug-02-18 08:54AM  The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: RXi Pharmaceuticals and Neurocrine Biosciences ACCESSWIRE
Aug-01-18 01:14PM  Here's Why Neurocrine Biosciences Stock Rose as Much as 14.3% Today Motley Fool +13.00%
11:40AM  Neurocrine stock rises 11% after Q2 revenue beat MarketWatch
Jul-31-18 04:28PM  Neurocrine: 2Q Earnings Snapshot Associated Press
04:01PM  Neurocrine Biosciences Reports Second Quarter 2018 Financial Results PR Newswire
02:30PM  Neurocrine Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Jul-24-18 01:46PM  AbbVie prices new endometriosis drug at $10,000 a year Reuters
08:30AM  AbbVie Receives U.S. FDA Approval of ORILISSA (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis PR Newswire
Jul-10-18 04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2018 Financial Results PR Newswire
Jul-05-18 07:25AM  Free Technical Reports on Novavax and Three Additional Biotech Equities ACCESSWIRE
Jun-27-18 06:01AM  3 Biotech Stocks With Major Potential Catalysts in July Motley Fool
Jun-20-18 07:52AM  5 Stocks That Are Screaming Buys Right Now TheStreet.com
Jun-08-18 04:56PM  Chief Executive Officer of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego PR Newswire
Jun-02-18 04:34PM  What You Must Know About Neurocrine Biosciences Incs (NASDAQ:NBIX) Financial Strength Simply Wall St.
May-22-18 07:00AM  Free Technical Insights on OPKO Health and Three Other Biotech Stocks ACCESSWIRE
May-14-18 08:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Fred's, Nexstar Broadcasting Group, CNO Financial Group, Neurocrine Biosciences, Kosmos Energy, and Loews New Research Emphasizes Economic Growth GlobeNewswire
May-09-18 04:01PM  Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference PR Newswire
06:00AM  3 Top Biotech Stocks to Buy in May Motley Fool
May-08-18 02:00PM  Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics PR Newswire
May-03-18 10:15AM  NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth Zacks Small Cap Research
May-02-18 04:14PM  Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting PR Newswire -5.11%
01:52PM  Edited Transcript of NBIX earnings conference call or presentation 30-Apr-18 9:00pm GMT Thomson Reuters StreetEvents
May-01-18 07:51AM  Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings Benzinga
Apr-30-18 04:21PM  Neurocrine: 1Q Earnings Snapshot Associated Press
04:01PM  Neurocrine Biosciences Reports First Quarter 2018 Financial Results PR Newswire
01:45PM  Neurocrine Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Apr-27-18 08:00AM  AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting PR Newswire
Apr-25-18 06:56PM  Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions PR Newswire
Apr-23-18 04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial Results PR Newswire
Apr-19-18 07:52AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Apr-18-18 04:01PM  Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting PR Newswire
Apr-10-18 10:16AM  FDA needs more time to review AbbVie, Neurocrine's uterine pain drug Reuters
09:05AM  UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug Reuters
09:05AM  FDA extends review for AbbVie, Neurocrine's uterine pain drug Reuters
08:15AM  AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain PR Newswire
08:07AM  A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund Star Forbes
Mar-28-18 06:04AM  3 Biotechs That Could Get Big Boosts in April Motley Fool
Mar-20-18 07:26AM  Loss-Making Neurocrine Biosciences Inc (NASDAQ:NBIX) Expected To Breakeven Simply Wall St.
Mar-13-18 03:00PM  Is This AbbVie's Next Blockbuster Drug? Motley Fool
Mar-07-18 01:15PM  Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire
Feb-21-18 08:34AM  AbbVie, Neurocrine shares rise after positive results for uterine fibroids drug MarketWatch
08:00AM  AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids PR Newswire
Feb-20-18 02:04PM  5 Stocks to Outperform in 2018s Volatile Market Investopedia
Feb-16-18 03:00PM  NBIX: Will File an NDA for Opicapone in 1H19 Zacks Small Cap Research
Feb-14-18 04:01PM  Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data PR Newswire
10:11AM  Edited Transcript of NBIX earnings conference call or presentation 13-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Feb-13-18 04:17PM  Neurocrine misses 4Q profit forecasts Associated Press
04:01PM  Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018 PR Newswire
12:30PM  Neurocrine Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Feb-08-18 01:15PM  Neurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare Conference PR Newswire -5.05%
Feb-07-18 07:15PM  Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $8.5 million of Shares GuruFocus.com
Feb-06-18 01:15PM  Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results PR Newswire
Jan-23-18 08:10AM  New Research Coverage Highlights Leidos, Neurocrine Biosciences, M&T Bank, PennyMac Financial Services, CTS, and S&T Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jan-11-18 10:17AM  Elagolix May Advance the Treatment Paradigm in Womens Health Market Realist
Jan-10-18 05:20PM  How Did Bioverativ Perform in 3Q17? Market Realist
03:49PM  Analysts Recommendations for Bioverativ in January 2018 Market Realist
Jan-09-18 08:02AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Jan-08-18 05:52AM  Should You Be Concerned About Neurocrine Biosciences Incs (NASDAQ:NBIX) -54.35% Earnings Decline? Simply Wall St.
Jan-07-18 01:01PM  Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer PR Newswire
01:00PM  Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones PR Newswire
Jan-02-18 04:01PM  Neurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-29-17 07:55AM  Is Neurocrine Biosciences Incs (NASDAQ:NBIX) Balance Sheet A Threat To Its Future? Simply Wall St.
Dec-19-17 11:42AM  Why Biotech Acadia May Be Undervalued By 40% Investopedia
Dec-15-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-13-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-12-17 08:10AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-11-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-07-17 01:15PM  Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference PR Newswire
08:02AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-05-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-04-17 04:01PM  Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms PR Newswire
Nov-29-17 04:01PM  Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting PR Newswire
08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-28-17 08:06AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-21-17 01:15PM  Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire
08:15AM  Detailed Research: Economic Perspectives on Nexstar Broadcasting Group, CECO Environmental, Performance Food Group, Neurocrine Biosciences, e.l.f. Beauty, and Big Lots What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-20-17 04:01PM  Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer PR Newswire
08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-16-17 09:42AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-15-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grigoriadis Dimitri E.Chief Research OfficerSep 04Option Exercise12.2132,749399,977115,691Sep 05 08:41 PM
Gano KyleChief Business Development OffAug 01Option Exercise8.6628,266244,784107,008Aug 03 04:08 PM
Grigoriadis Dimitri E.Chief Research OfficerAug 01Option Exercise19.5923,022451,001105,964Aug 03 04:07 PM
Grigoriadis Dimitri E.Chief Research OfficerAug 01Sale110.0023,0222,532,42082,942Aug 03 04:07 PM
Gano KyleChief Business Development OffAug 01Sale115.0028,2663,250,59078,742Aug 03 04:08 PM
GORMAN KEVIN CHARLESChief Executive OfficerJun 28Option Exercise9.2157,924533,416404,957Jun 29 07:32 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 20Option Exercise19.5923,000450,570105,942Jun 21 06:16 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 20Sale105.0023,0002,415,00082,942Jun 21 06:16 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 14Option Exercise19.592,78554,55885,727Jun 15 04:44 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 14Sale100.002,785278,50082,942Jun 15 04:44 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 13Option Exercise11.2884,178949,292146,905Jun 15 04:44 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 13Sale99.4684,1788,372,23882,942Jun 15 04:44 PM
LYONS GARY ADirectorJun 13Sale99.2415,0001,488,549260,697Jun 15 04:45 PM
SHERWIN STEPHEN ADirectorJun 11Sale98.4410,000984,42047,548Jun 13 12:34 PM
BENEVICH ERICChief Commercial OfficerJun 01Sale97.3412,3501,202,16416,690Jun 05 06:53 PM
Nevinny Corinne HDirectorMay 07Sale83.135,000415,62543,283May 09 06:12 PM
Nevinny Corinne HDirectorMay 02Option Exercise7.0515,000105,75049,603May 03 07:53 PM
GORMAN KEVIN CHARLESChief Executive OfficerMay 01Option Exercise5.76126,832730,552473,865May 03 07:39 PM
POPS RICHARD FDirectorMay 01Option Exercise7.0515,000105,75044,512May 03 07:42 PM
GORMAN KEVIN CHARLESChief Executive OfficerMay 01Sale80.75126,83210,241,735347,033May 03 07:39 PM
SHERWIN STEPHEN ADirectorApr 26Option Exercise7.0515,000105,75058,879Apr 30 04:03 PM
LYONS GARY ADirectorApr 03Option Exercise7.0515,000105,750277,066Apr 05 06:52 PM
Gano KyleChief Business Development OffMar 05Option Exercise8.6523,650204,573102,392Mar 07 04:16 PM
Bozigian Haig P.Chief Development OfficerMar 05Option Exercise12.8775,873976,703197,471Mar 07 04:13 PM
Lippoldt DarinChief Legal OfficerMar 05Option Exercise18.151,97935,91918,041Mar 07 04:18 PM
Lippoldt DarinChief Legal OfficerMar 05Sale88.471,979175,09016,062Mar 07 04:18 PM
Gano KyleChief Business Development OffMar 05Sale90.0023,6502,128,50078,742Mar 07 04:16 PM
Bozigian Haig P.Chief Development OfficerMar 05Sale90.0075,8736,828,570135,997Mar 07 04:13 PM
LYONS GARY ADirectorFeb 15Sale84.675,000423,341262,066Feb 20 04:02 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 12Option Exercise8.6614,593126,37597,535Feb 13 04:12 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 12Sale80.0014,5931,167,45382,942Feb 13 04:12 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 09Option Exercise8.6671,775621,572154,717Feb 13 04:12 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 09Sale77.9871,7755,596,72082,942Feb 13 04:12 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Option Exercise5.76100,000576,000442,874Feb 07 06:06 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Sale80.07100,0008,006,620342,874Feb 07 06:06 PM
Lippoldt DarinChief Legal OfficerFeb 05Option Exercise18.151,97935,91915,136Feb 07 06:07 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale83.265,983498,164339,482Feb 07 06:06 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale83.1482068,1742,577Feb 07 06:00 PM
LYONS GARY ADirectorFeb 05Sale83.085,000415,380267,066Feb 07 06:08 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale83.122,737227,49413,157Feb 07 06:07 PM
Gano KyleChief Business Development OffFeb 05Sale83.052,046169,91476,950Feb 07 05:59 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale83.1996079,86313,982Feb 07 06:07 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale83.102,262187,977132,601Feb 07 06:05 PM
OBrien Christopher FlintFormer Chief Medical OfficerFeb 05Sale83.182,613217,34152,223Feb 07 06:08 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale83.092,046169,99780,691Feb 07 06:06 PM
RASTETTER WILLIAM HDirectorJan 24Option Exercise7.0520,000141,00034,250Jan 26 04:04 PM
RASTETTER WILLIAM HDirectorJan 24Sale90.009,500855,00024,750Jan 26 04:04 PM
Grigoriadis Dimitri E.Chief Research OfficerJan 16Sale79.121,625128,56379,316Jan 18 04:10 PM
GORMAN KEVIN CHARLESChief Executive OfficerJan 16Sale78.893,750295,820336,357Jan 18 04:09 PM
Bozigian Haig P.Chief Development OfficerJan 16Sale79.121,625128,575131,226Jan 18 04:07 PM
Gano KyleChief Business Development OffJan 16Sale79.051,625128,46074,871Jan 18 04:08 PM
OBrien Christopher FlintChief Medical OfficerJan 16Sale79.141,750138,49950,723Jan 18 04:12 PM
Lippoldt DarinChief Legal OfficerJan 03Option Exercise18.151,97935,91915,136Jan 04 04:07 PM
Lippoldt DarinChief Legal OfficerJan 03Sale79.361,979157,05313,157Jan 04 04:07 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 02Option Exercise15.4518,084279,39831,101Jan 04 04:05 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 02Sale77.5218,0841,401,82313,017Jan 04 04:05 PM
Lippoldt DarinChief Legal OfficerDec 28Option Exercise18.1515,237276,55228,394Jan 02 04:02 PM
Lippoldt DarinChief Legal OfficerDec 28Sale75.0015,2371,142,77513,157Jan 02 04:02 PM
Lippoldt DarinChief Legal OfficerDec 08Option Exercise18.152,95553,63316,112Dec 11 04:48 PM
Lippoldt DarinChief Legal OfficerDec 08Sale75.002,955221,62513,157Dec 11 04:48 PM
Lippoldt DarinChief Legal OfficerDec 04Option Exercise18.156,279113,96419,436Dec 06 04:59 PM
Lippoldt DarinChief Legal OfficerDec 04Sale75.046,279471,16013,157Dec 06 04:59 PM
LYONS GARY ADirectorDec 01Sale72.9210,000729,182272,066Dec 05 04:31 PM
Lippoldt DarinChief Legal OfficerNov 15Option Exercise18.159,900179,68523,057Nov 17 04:29 PM
Lippoldt DarinChief Legal OfficerNov 15Sale73.059,900723,19113,157Nov 17 04:29 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 08Sale74.5830,0002,237,34377,691Nov 13 04:15 PM
OBrien Christopher FlintChief Medical OfficerNov 02Option Exercise8.6652,817457,32094,272Nov 06 04:45 PM
Gano KyleChief Business Development OffNov 02Option Exercise8.6624,818214,81086,714Nov 06 04:44 PM
OBrien Christopher FlintChief Medical OfficerNov 02Sale69.7152,8173,681,64148,973Nov 06 04:45 PM
Gano KyleChief Business Development OffNov 02Sale71.0524,8181,763,31973,246Nov 06 04:44 PM